Free Weekly Health Brief
HomeAboutTopicsNewsletterCommunity
Free Weekly Health Brief
Free Weekly Health Brief
HomeAboutTopicsNewsletterCommunity
Free Weekly Health Brief
Doctor in a white coat speaking with an older male patient at a clinic desk
Cancer Prevention

Why Today's Prostate Cancer Patients Have More Options Than Ever

Published: May 28, 2026  ·  Last updated: May 28, 2026

This week's brief at a glance:
  • Active surveillance is now the recommended starting path for many men with low-risk localized prostate cancer (NCI, 2024)
  • PSMA-targeted PET imaging and radioligand therapy have changed how advanced prostate cancer is staged and treated (Mayo Clinic, 2024)
  • Focal therapies, including HIFU and cryotherapy, can preserve function in selected men whose cancer is contained to one zone of the prostate (Johns Hopkins Medicine, 2024)

A prostate cancer diagnosis 20 years ago meant a quick choice between surgery and radiation, with side effects most men were told to accept. The conversation today is different.

Newer imaging shows the disease earlier and more precisely. Active surveillance keeps a slow tumor under watch instead of removing the organ that contains it. Focal therapy treats one zone of the prostate while leaving the rest intact. And for advanced disease, a class of drugs that targets a single protein on cancer cells has changed the late-stage map. Most men hearing the diagnosis this year have more genuine choices than men diagnosed in 2005.

The Risk Tier Drives Everything Else

Low, Intermediate, and High Are Not Casual Labels: The first decision is risk classification, built from PSA level, Gleason grade group, and clinical stage. Low-risk localized cancer behaves differently than intermediate or high-risk disease, and the recommended starting paths split there (National Cancer Institute, 2024).

Active surveillance, surgery, radiation, hormone therapy, and newer focal options all have a place. Which one fits depends on the tier first and personal priorities second.

Active Surveillance Is Not "Doing Nothing"

Watch With a Schedule, Not Without One: For men with low-risk cancer that is small and slow, the evidence supports starting with active surveillance: serial PSA, repeat MRI, and a follow-up biopsy on a defined schedule. Treatment kicks in if the cancer shows signs of progression, not before.

The trade is real. Active surveillance keeps continence and erectile function intact for the period it lasts. The cost is the ongoing testing and the knowledge that a tumor is being watched rather than removed.

Surgery and Radiation Are Now More Targeted

Two Mature Options With Different Profiles: Radical prostatectomy and external beam radiation remain the two main definitive treatments for localized disease. Both have improved technically, with robotic-assisted surgery and more precise radiation planning reducing collateral damage to nearby nerves and tissues (Mayo Clinic, 2024).

Side effect profiles differ. Surgery has a sharper early impact on continence; radiation has a slower, later effect on bowel and urinary function. Neither is "better" in general. Both are options for many men.

Focal Therapy and Advanced Treatments Are New Real Choices

Treat the Lesion, Spare the Organ: Focal therapies such as HIFU, cryotherapy, and irreversible electroporation aim to destroy a single tumor zone while preserving the rest of the prostate. They are appropriate for a subset of men with cancer confined to one area on imaging and biopsy (Johns Hopkins Medicine, 2024).

For advanced or castration-resistant disease, PSMA-targeted radioligand therapy and newer androgen receptor antagonists like enzalutamide, apalutamide, and darolutamide have changed what late-stage treatment looks like.

How to Make the Decision Without Rushing It

Two Opinions Beat One in This Disease: Most localized prostate cancers do not require a same-week decision. Use the time to get a second opinion from a multidisciplinary clinic where a urologic surgeon, radiation oncologist, and medical oncologist all weigh in.

Bring your own priorities to the visit: continence, erectile function, fatigue tolerance, travel demands, and how long the regimen runs. Treatment menus look different once those weights are explicit.

Your Coach's Recommendations
1
Ask Your Urologist Your Specific Risk Tier in Writing.
Get the Gleason grade group, PSA, and clinical stage written down. That trio drives every conversation that follows.
2
Request a Multidisciplinary Second Opinion Before Choosing Treatment.
A tumor board visit at an academic cancer center bundles urology, radiation, and medical oncology into one structured review of your specific case.
3
Write Down Your Top Three Priorities Before the Decision Visit.
Continence, sexual function, fatigue tolerance, recovery time. Bring the list. Doctors weigh trade-offs more carefully when patients articulate them first.

To your health,

AC

Ageless Coach

Age Strong. Live Long.

Trusted Sources Behind This Article

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reading this article does not create a provider-patient relationship. Always consult your physician or qualified healthcare provider before making changes to your diet, exercise, or health routine. Ageless Coach is not liable for any actions taken based on this information.

Frequently Asked Questions

How do I know if I am a candidate for active surveillance?
Eligibility centers on a low-risk classification, small tumor volume, and patient willingness to follow a strict imaging and biopsy schedule. Your urologist will lay out the specific criteria.
Is robotic surgery better than open prostatectomy?
Robotic-assisted surgery generally has shorter hospital stays and less blood loss. Long-term cancer control and side-effect outcomes depend more on surgeon volume and experience than on the platform.
What is PSMA imaging and how does it change my care?
PSMA PET/CT detects prostate cancer cells with high sensitivity using a tracer that binds to a protein on the cancer surface. It is most useful for staging higher-risk disease and locating recurrence after treatment.
When is focal therapy appropriate?
Focal therapy works best for cancer confined to a single zone of the prostate on imaging and biopsy. It is not appropriate for diffuse or multifocal disease.
How long do I have to decide on a treatment plan?
Most localized prostate cancers grow slowly enough that you can take 4 to 8 weeks for second opinions and shared decision making. Your urologist will flag any urgency.
Can I keep exercising and lifting weights during treatment?
Yes, with adjustments. Resistance training during hormone therapy specifically helps preserve muscle and bone. Your oncology team will tailor the plan to the treatment phase.

Want one verified-science article like this every week?

Get Better Health, Weekly